XDR-TB, What is it; How is it Treated; and why is Therapeutic Failure so High?

E-ISSN： 2212-4071|6|2|77-83

ISSN： 1574-891X

Source： Recent Patents on Anti-Infective Drug Discovery, Vol.6, Iss.2, 2011-05, pp. : 77-83

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB

Recent Patents on Anti-Infective Drug Discovery, Vol. 6, Iss. 2, 2011-05 ,pp. : 88-91

Bentham Science Publishers

Access to resources Recommend Favorite

Stem Cells in MDR-TB and XDR - TB

Current Respiratory Medicine Reviews, Vol. 10, Iss. 4, 2014-12 ,pp. : 238-240

Bentham Science Publishers

Access to resources Recommend Favorite

Stem Cells in MDR-TB and XDR - TB

Current Respiratory Medicine Reviews, Vol. 10, Iss. 4, 2015-05 ,pp. : 238-240

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Human Macrophage with Combinations of Drugs and Inhibitors of Ca2+ and K+ Transport to Enhance the Killing of Intracellular Multi-Drug Resistant Mycobacterium tuberculosis (MDR-TB) - a Novel, Patentable Approach to Limit the Emergence of XDR-TB

Recent Patents on Anti-Infective Drug Discovery, Vol. 6, Iss. 2, 2011-05 ,pp. : 110-117

Bentham Science Publishers

Access to resources Recommend Favorite

MDR/XDRTB: What are the New Treatment Options?

Current Respiratory Medicine Reviews, Vol. 9, Iss. 3, 2013-06 ,pp. : 211-216

Bentham Science Publishers

Access to resources Recommend Favorite